Pharmacological inhibition of ezrin reduces proliferative and invasive phenotype in acute lymphoblastic leukemia cells.

Autor: Lipreri da Silva JC; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Lima K; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Division of Hematology, Hemotherapy and Cell Therapy, Medical School Clinic Hospital, University of São Paulo, São Paulo, Brazil., Ede B; School of Cellular and Molecular Medicine, Faculty of Health and Life Sciences, University of Bristol, Bristol, United Kingdom., Lazarini M; Department of Clinical and Experimental Oncology, Federal University of São Paulo, São Paulo, Brazil., Vicari HP; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Nogueira FL; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Division of Hematology, Hemotherapy and Cell Therapy, Medical School Clinic Hospital, University of São Paulo, São Paulo, Brazil., Clayton NS; School of Cellular and Molecular Medicine, Faculty of Health and Life Sciences, University of Bristol, Bristol, United Kingdom., Pinnell K; School of Cellular and Molecular Medicine, Faculty of Health and Life Sciences, University of Bristol, Bristol, United Kingdom., Silva WFD; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Division of Hematology, Hemotherapy and Cell Therapy, Medical School Clinic Hospital, University of São Paulo, São Paulo, Brazil., Velloso EDRP; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Division of Hematology, Hemotherapy and Cell Therapy, Medical School Clinic Hospital, University of São Paulo, São Paulo, Brazil., Bendit I; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Division of Hematology, Hemotherapy and Cell Therapy, Medical School Clinic Hospital, University of São Paulo, São Paulo, Brazil., Costa-Lotufo LV; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil., Rego EM; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Division of Hematology, Hemotherapy and Cell Therapy, Medical School Clinic Hospital, University of São Paulo, São Paulo, Brazil., Ridley AJ; School of Cellular and Molecular Medicine, Faculty of Health and Life Sciences, University of Bristol, Bristol, United Kingdom., Machado-Neto JA; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Electronic address: jamachadoneto@usp.br.

Publikováno v: European journal of pharmacology [Eur J Pharmacol] 2025 Jan 15; Vol. 987, pp. 177161. Date of Electronic Publication: 2024 Nov 29.

How I treat older patients with Ph/BCR-ABL-negative acute lymphoblastic leukemia.

Autor: Gökbuget N; Department of Medicine II, Hematology/Oncology, Goethe University, University Hospital, Frankfurt, Germany., Steffen B; Department of Medicine II, Hematology/Oncology, Goethe University, University Hospital, Frankfurt, Germany.

Publikováno v: Blood [Blood] 2025 Jan 02; Vol. 145 (1), pp. 53-63.

How I treat infant acute lymphoblastic leukemia.

Autor: Bartram J; Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom., Ancliff P; Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom., Vora A; Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom.

Publikováno v: Blood [Blood] 2025 Jan 02; Vol. 145 (1), pp. 35-42.

Systematic Review of Pain Assessment Measures Used in Pediatric Acute Lymphoblastic Leukemia.

Autor: Klages KL; Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Gibson CA; Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA., Barnett KA; Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Schwartz LE; Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Hicks CA; Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA., Norris RE; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Kashikar-Zuck S; Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Pai ALH; Center for Biobehavioral Health, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, USA.; Department of Pediatrics, The Ohio State University School of Medicine, Columbus, Ohio, USA.

Publikováno v: Psycho-oncology [Psychooncology] 2025 Jan; Vol. 34 (1), pp. e70063.

Contribution of Cyclin Dependent Kinase Inhibitor 1A Genotypes to Childhood Acute Lymphocytic Leukemia Risk in Taiwan.

Autor: Chen CC; Department of Pediatrics, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan, R.O.C., Tsai CL; Division of Cardiac and Vascular Surgery, Cardiovascular Center, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C., Pei JS; Department of Pediatrics, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan, R.O.C., Tzeng HE; Division of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, and Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan, R.O.C., Hsu PC; Department of Pediatrics, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan, R.O.C., Cheng DC; Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan, R.O.C., Lin JC; Division of Cardiology, Department of Internal Medicine, Taichung Veterans General Hospital, Chiayi Branch, Chiayi, Taiwan, R.O.C., Tsai CW; Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C., Bau DT; Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.; 013280@tool.caaumed.org.tw.; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.; Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan, R.O.C., Chang WS; Terry Fox Cancer Research Laboratory, China Medical University Hospital, Taichung, Taiwan, R.O.C.; 031002@tool.caaumed.org.tw.; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.

Publikováno v: Cancer genomics & proteomics [Cancer Genomics Proteomics] 2025 Jan-Feb; Vol. 22 (1), pp. 46-54.